Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-Line Pazopanib in Poor-Risk Metastatic Renal Cell Carcinoma
2011-001138-40Phase 4Completed
- Sponsor
- iOMEDICO
- Start
- Sep 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pazopanib in renal cell carcinoma (RCC), sponsored by iOMEDICO. Primary endpoint: Progression-free at 6 months in poor-risk patients. Started Sep 2011; status: completed.
02
Drugs
pazopanib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2011-001138-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001138-40.